Literature DB >> 17994473

The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance.

William W Stoops1, Joshua A Lile, Michelle R Lofwall, Craig R Rush.   

Abstract

Although cocaine dependence remains a significant public health concern, efforts to identify a pharmacotherapy have been unsuccessful. The purpose of this study was to assess the safety, tolerability, and subject-rated effects of intranasal cocaine during maintenance on aripiprazole, a novel antipsychotic with partial agonist activity at monoamine receptors implicated in the effects of cocaine. To this end, eight cocaine dependent subjects were maintained on 10 mg oral aripiprazole and placebo in counterbalanced order prior to assessing the physiological and subject-rated effects of intranasal cocaine (4, 20, 40, and 60 mg). Aripiprazole was generally devoid of effects, but did alter temperature-increasing and subject-rated effects of cocaine as a function of cocaine dose.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17994473     DOI: 10.1080/00952990701651556

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  15 in total

1.  Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy.

Authors:  Craig R Rush; William W Stoops; Lon R Hays
Journal:  Drug Alcohol Depend       Date:  2008-10-15       Impact factor: 4.492

2.  Physiological and subjective effects of acute intranasal methamphetamine during extended-release alprazolam maintenance.

Authors:  Joshua A Lile; William W Stoops; Paul E A Glaser; Lon R Hays; Craig R Rush
Journal:  Drug Alcohol Depend       Date:  2011-07-06       Impact factor: 4.492

3.  Effects of Acute and Chronic Treatments with Dopamine D2 and D3 Receptor Ligands on Cocaine versus Food Choice in Rats.

Authors:  Morgane Thomsen; Andrew C Barrett; Paul Butler; S Stevens Negus; S Barak Caine
Journal:  J Pharmacol Exp Ther       Date:  2017-05-04       Impact factor: 4.030

4.  Aripiprazole maintenance increases smoked cocaine self-administration in humans.

Authors:  Margaret Haney; Eric Rubin; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2011-03-05       Impact factor: 4.530

5.  Effects of repeated treatment with the dopamine D2/D3 receptor partial agonist aripiprazole on striatal D2/D3 receptor availability in monkeys.

Authors:  Paul W Czoty; H Donald Gage; Pradeep K Garg; Sudha Garg; Michael A Nader
Journal:  Psychopharmacology (Berl)       Date:  2013-09-29       Impact factor: 4.530

6.  Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse.

Authors:  Matthew W Feltenstein; Phong H Do; Ronald E See
Journal:  Psychopharmacology (Berl)       Date:  2009-09-25       Impact factor: 4.530

7.  The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period.

Authors:  Joshua A Lile; William W Stoops; Lon R Hays; Craig R Rush
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

8.  Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans.

Authors:  Michelle R Lofwall; Paul A Nuzzo; Charles Campbell; Sharon L Walsh
Journal:  Exp Clin Psychopharmacol       Date:  2014-01-27       Impact factor: 3.157

9.  Effects of dopamine D2/D3 receptor ligands on food-cocaine choice in socially housed male cynomolgus monkeys.

Authors:  Paul W Czoty; Michael A Nader
Journal:  J Pharmacol Exp Ther       Date:  2012-12-04       Impact factor: 4.030

10.  Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats.

Authors:  Morgane Thomsen; Anders Fink-Jensen; David P D Woldbye; Gitta Wörtwein; Thomas N Sager; Rene Holm; Lauren M Pepe; S Barak Caine
Journal:  Psychopharmacology (Berl)       Date:  2008-07-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.